Display Settings:

Format

Send to:

Choose Destination
    Ann Thorac Surg. 2006 Jun;81(6):S2355-9.

    Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients.

    Source

    Department of Pathology and Medicine, Doernbecher Children's Hospital, Oregon Health and Science University, Portland, Oregon 97231, USA. boshkovl@ohsu.edu

    Abstract

    Repeated exposure to unfractionated heparin is the rule in many congenital heart disease patients. Heparin-induced thrombocytopenia occurs in 1% to 3% of adult cardiac surgeries, and carries high thrombotic morbidity (38% to 81%) and mortality (approximately 28%). Although heparin-induced thrombocytopenia appears to be infrequent in pediatric patients, particularly neonates, our evolving experience suggests postcardiopulmonary bypass congenital heart disease patients may be at increased risk. Diagnostic and therapeutic challenges include frequency of thrombocytopenia after cardiopulmonary bypass, imperfect laboratory testing, lack of established dosing of alternative anticoagulants (such as argatroban and lepirudin), and increased anticoagulant-related bleeding in young children.

    PMID:
    16731103
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk